| 5-hydroxytryptamine (serotonin) receptor 2B |
MITOTANE |
Serotonin 5-HT2B |
73% |
4.832uM |
3.075uM |
View
|
| cholinergic receptor, muscarinic 5 |
TROPISETRON |
Muscarinic M5 |
73% |
3.45uM |
2.479uM |
View
|
| histamine receptor H 2 |
KETOTIFEN |
Histamine H2 |
73% |
4.129uM |
4.06uM |
View
|
| adrenergic receptor, beta 1 |
CLORPRENALINE |
Adrenergic beta1 |
73% |
2.592uM |
1.497uM |
View
|
| adrenergic, beta-1-, receptor |
CLORPRENALINE |
Adrenergic beta1 |
73% |
2.592uM |
1.497uM |
View
|
| Cytochrom P450-1A2 monooxygenase |
PROPRANOLOL |
CYP450-1A2 Inhibition |
73% |
4uM |
NoneNone |
View
|
| Cytochrom P450-1A2 monooxygenase |
OXICONAZOLE |
CYP450-1A2 Inhibition |
68% |
NoneNone |
NoneNone |
View
|
| mitogen activated protein kinase 1 |
ACECLOFENAC |
Protein Serine/Threonine Kinase, ERK2 |
73% |
5.927uM |
NoneNone |
View
|
| mitogen-activated protein kinase 1 |
ACECLOFENAC |
Protein Serine/Threonine Kinase, ERK2 |
73% |
5.927uM |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
OXYBUTYNIN |
Adrenergic, Norepinephrine Transporter |
73% |
2.5951uM |
2.5737uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2B |
ORPHENADRINE |
Serotonin 5-HT2B |
73% |
3.391uM |
2.158uM |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, nonvoltage-gated 1 gamma |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, nonvoltage-gated 1 beta |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, nonvoltage-gated 1, gamma |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, nonvoltage-gated 1, delta |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type X, alpha |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type IX, alpha |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage gated, type VIII, alpha |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type VII, alpha |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type IV, beta |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type IV, alpha |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type III, alpha |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type II, beta |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type II, alpha 2 |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type I, beta |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type I, alpha |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| adrenergic receptor, alpha 2b |
OXYMETAZOLINE |
Adrenergic alpha2C |
73% |
2.633uM |
.383uM |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
OXYMETAZOLINE |
Adrenergic alpha2C |
73% |
2.633uM |
.383uM |
View
|
| sodium channel, voltage-gated, type IV, beta |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel associated protein 1 |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel associated protein 2 |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type III, beta |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type I, alpha |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type IX, alpha |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type VII, alpha |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| amiloride-sensitive cation channel 5, intestinal |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type III, beta |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type VIII, alpha polypeptide |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type I, beta |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| sodium channel, voltage-gated, type 10, alpha polypeptide |
OXYMETAZOLINE |
Sodium Channel, Site 2 |
73% |
3.45uM |
3.148uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
DIPHENIDOL |
Calcium Channel Type L, Phenylalkylamine |
73% |
4.501uM |
4.376uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
DIPHENIDOL |
Calcium Channel Type L, Phenylalkylamine |
73% |
4.501uM |
4.376uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
DIPHENIDOL |
Calcium Channel Type L, Phenylalkylamine |
73% |
4.501uM |
4.376uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
DIPHENIDOL |
Calcium Channel Type L, Phenylalkylamine |
73% |
4.501uM |
4.376uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
DIPHENIDOL |
Calcium Channel Type L, Phenylalkylamine |
73% |
4.501uM |
4.376uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
DIPHENIDOL |
Calcium Channel Type L, Phenylalkylamine |
73% |
4.501uM |
4.376uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
DIPHENIDOL |
Calcium Channel Type L, Phenylalkylamine |
73% |
4.501uM |
4.376uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
DIPHENIDOL |
Calcium Channel Type L, Phenylalkylamine |
73% |
4.501uM |
4.376uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
DIPHENIDOL |
Calcium Channel Type L, Phenylalkylamine |
73% |
4.501uM |
4.376uM |
View
|
| adrenergic receptor, alpha 1b |
DIPHENIDOL |
Adrenergic alpha1B |
73% |
4.76uM |
2.635uM |
View
|
| dopamine receptor 2 |
DIPHENIDOL |
Dopamine D2L |
73% |
3.29uM |
1.097uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1A |
CLONIDINE |
Serotonin 5-HT1A |
73% |
5.365uM |
3.066uM |
View
|
| opioid receptor, sigma 1 |
BUTENAFINE |
Sigma1 |
73% |
3.9533uM |
1.6615uM |
View
|
| Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) |
DIHYDROERGOCRISTINE MESYLATE |
CYP450-2C9 Inhibition |
73% |
3uM |
NoneNone |
View
|
| cytochrome P450, family 2, subfamily C, polypeptide 9 |
DIHYDROERGOCRISTINE MESYLATE |
CYP450-2C9 Inhibition |
73% |
3uM |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
TERBINAFINE |
Adrenergic, Norepinephrine Transporter |
73% |
4.1295uM |
4.0954uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1A |
PROCHLORPERAZINE |
Serotonin 5-HT1A |
73% |
.95uM |
.543uM |
View
|
| Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) |
TROGLITAZONE |
CYP450-2C9 Inhibition |
73% |
4uM |
NoneNone |
View
|
| cytochrome P450, family 2, subfamily C, polypeptide 9 |
TROGLITAZONE |
CYP450-2C9 Inhibition |
73% |
4uM |
NoneNone |
View
|
| mu-opioid receptor MOR |
DISULFIRAM |
Opiate mu |
73% |
3.511uM |
1.425uM |
View
|
| progesterone receptor |
MICONAZOLE |
Progesterone |
73% |
14.912uM |
1.945uM |
View
|
| progesterone receptor |
MICONAZOLE |
Progesterone |
73% |
14.912uM |
1.945uM |
View
|
| solute carrier family 28 (sodium-coupled nucleoside transporter), member 3 |
PREDNISONE |
Adenosine Transporter |
73% |
4.947uM |
1.692uM |
View
|
| concentrative Na+ nucleoside cotransporter (DBSS) |
PREDNISONE |
Adenosine Transporter |
73% |
4.947uM |
1.692uM |
View
|
| solute carrier family 28 (sodium-coupled nucleoside transporter), member 1 |
PREDNISONE |
Adenosine Transporter |
73% |
4.947uM |
1.692uM |
View
|
| adenine nucleotide translocase (DBSS) (Non-specific probe) |
PREDNISONE |
Adenosine Transporter |
73% |
4.947uM |
1.692uM |
View
|
| solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4 |
PREDNISONE |
Adenosine Transporter |
73% |
4.947uM |
1.692uM |
View
|
| progesterone receptor |
ECONAZOLE |
Progesterone |
73% |
10.208uM |
1.332uM |
View
|
| progesterone receptor |
ECONAZOLE |
Progesterone |
73% |
10.208uM |
1.332uM |
View
|
| melanocortin 3 receptor |
ECONAZOLE |
Melanocortin MC3 |
73% |
36.009uM |
31.426uM |
View
|
| melanocortin 3 receptor |
ECONAZOLE |
Melanocortin MC3 |
73% |
36.009uM |
31.426uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2C |
MICONAZOLE |
Serotonin 5-HT2C |
73% |
5.314uM |
2.784uM |
View
|
| dopamine receptor D1A |
DANAZOL |
Dopamine D1 |
73% |
20.449uM |
10.225uM |
View
|
| adrenergic receptor, beta 1 |
DIETHYLSTILBESTROL |
Adrenergic beta1 |
73% |
22.088uM |
12.755uM |
View
|
| adrenergic, beta-1-, receptor |
DIETHYLSTILBESTROL |
Adrenergic beta1 |
73% |
22.088uM |
12.755uM |
View
|
| opioid receptor, kappa 1 |
MIFEPRISTONE |
Opiate kappa |
73% |
20.096uM |
8.038uM |
View
|
| prostaglandin-endoperoxide synthase 1 |
4-OCTYLPHENOL |
Cyclooxygenase COX-1 |
73% |
10.319uM |
NoneNone |
View
|
| prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) |
4-OCTYLPHENOL |
Cyclooxygenase COX-1 |
73% |
10.319uM |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1B |
BACITRACIN |
Serotonin 5-HT1B |
73% |
2.978uM |
1.354uM |
View
|
| nuclear receptor subfamily 3, group C, member 1 |
TESTOSTERONE |
Glucocorticoid |
73% |
3.206uM |
1.457uM |
View
|
| phosphodiesterase 4A, cAMP specific |
ALPHA-NAPHTHOFLAVONE |
Phosphodiesterase PDE4 |
73% |
2.9197uM |
NoneNone |
View
|
| phosphodiesterase 4C, cAMP-specific |
ALPHA-NAPHTHOFLAVONE |
Phosphodiesterase PDE4 |
73% |
2.9197uM |
NoneNone |
View
|
| phosphodiesterase 4D |
ALPHA-NAPHTHOFLAVONE |
Phosphodiesterase PDE4 |
73% |
2.9197uM |
NoneNone |
View
|
| phosphodiesterase 4B, cAMP specific |
ALPHA-NAPHTHOFLAVONE |
Phosphodiesterase PDE4 |
73% |
2.9197uM |
NoneNone |
View
|
| arachidonate 15-lipoxygenase, second type |
DOXORUBICIN |
Lipoxygenase 15-LO |
73% |
13.59uM |
NoneNone |
View
|
| arachidonate 15-lipoxygenase |
DOXORUBICIN |
Lipoxygenase 15-LO |
73% |
13.59uM |
NoneNone |
View
|
| arachidonate 15-lipoxygenase |
DOXORUBICIN |
Lipoxygenase 15-LO |
73% |
13.59uM |
NoneNone |
View
|
| caspase 1 |
DOXORUBICIN |
Protease, Caspase 1 |
73% |
12.192uM |
NoneNone |
View
|
| caspase 1, apoptosis-related cysteine protease (interleukin 1, beta, convertase) |
DOXORUBICIN |
Protease, Caspase 1 |
73% |
12.192uM |
NoneNone |
View
|
| caspase 3, apoptosis related cysteine protease |
DOXORUBICIN |
Protease, Caspase 1 |
73% |
12.192uM |
NoneNone |
View
|
| caspase 2 |
DOXORUBICIN |
Protease, Caspase 1 |
73% |
12.192uM |
NoneNone |
View
|
| caspase 7 |
DOXORUBICIN |
Protease, Caspase 1 |
73% |
12.192uM |
NoneNone |
View
|
| caspase 6 |
DOXORUBICIN |
Protease, Caspase 1 |
73% |
12.192uM |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
AMLODIPINE |
Dopamine Transporter |
73% |
5.521uM |
4.387uM |
View
|
| androgen receptor |
CLOTRIMAZOLE |
Testosterone |
73% |
11.586uM |
7.724uM |
View
|
| histamine receptor H 2 |
CLOTRIMAZOLE |
Histamine H2 |
73% |
5.165uM |
5.079uM |
View
|
| chemokine (C-C motif) receptor 4 |
AMIODARONE |
Chemokine CCR4 |
73% |
21.773uM |
11.405uM |
View
|
| angiotensin 1 converting enzyme 1 |
BLEOMYCIN A2 |
Protease, Angiotensin Converting Enzyme |
73% |
.588uM |
NoneNone |
View
|
| angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
BLEOMYCIN A2 |
Protease, Angiotensin Converting Enzyme |
73% |
.588uM |
NoneNone |
View
|
| Cytochrom P450-2D6 monooxygenase |
1-BENZYLIMIDAZOLE |
CYP450-2D6 Inhibition |
73% |
2uM |
NoneNone |
View
|
| melanocortin 3 receptor |
TAMOXIFEN |
Melanocortin MC3 |
73% |
19.856uM |
17.329uM |
View
|
| melanocortin 3 receptor |
TAMOXIFEN |
Melanocortin MC3 |
73% |
19.856uM |
17.329uM |
View
|
| dopamine receptor D1A |
DIHYDROERGOTAMINE |
Dopamine D1 |
73% |
2.395uM |
1.197uM |
View
|
| Sigma-2 Receptor |
CLOMIPRAMINE |
Sigma2 |
73% |
1.876uM |
1.155uM |
View
|
| cytochrome P450, family 3, subfamily a, polypeptide 13 |
MAPROTILINE |
CYP450-3A4 Inhibition |
73% |
4.322uM |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
BW-723C86 |
Calcium Channel Type L, Benzothiazepine |
73% |
3.4696uM |
3.0841uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
BW-723C86 |
Calcium Channel Type L, Benzothiazepine |
73% |
3.4696uM |
3.0841uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
BW-723C86 |
Calcium Channel Type L, Benzothiazepine |
73% |
3.4696uM |
3.0841uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
BW-723C86 |
Calcium Channel Type L, Benzothiazepine |
73% |
3.4696uM |
3.0841uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
BW-723C86 |
Calcium Channel Type L, Benzothiazepine |
73% |
3.4696uM |
3.0841uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
BW-723C86 |
Calcium Channel Type L, Benzothiazepine |
73% |
3.4696uM |
3.0841uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
BW-723C86 |
Calcium Channel Type L, Benzothiazepine |
73% |
3.4696uM |
3.0841uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
BW-723C86 |
Calcium Channel Type L, Benzothiazepine |
73% |
3.4696uM |
3.0841uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
BW-723C86 |
Calcium Channel Type L, Benzothiazepine |
73% |
3.4696uM |
3.0841uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
BW-723C86 |
Calcium Channel Type L, Benzothiazepine |
73% |
3.4696uM |
3.0841uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
BW-723C86 |
Calcium Channel Type L, Benzothiazepine |
73% |
3.4696uM |
3.0841uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
BW-723C86 |
Calcium Channel Type L, Benzothiazepine |
73% |
3.4696uM |
3.0841uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
BW-723C86 |
Calcium Channel Type L, Benzothiazepine |
73% |
3.4696uM |
3.0841uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
BW-723C86 |
Calcium Channel Type L, Benzothiazepine |
73% |
3.4696uM |
3.0841uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
BW-723C86 |
Calcium Channel Type L, Benzothiazepine |
73% |
3.4696uM |
3.0841uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
BW-723C86 |
Calcium Channel Type L, Benzothiazepine |
73% |
3.4696uM |
3.0841uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
BW-723C86 |
Calcium Channel Type L, Benzothiazepine |
73% |
3.4696uM |
3.0841uM |
View
|
| Sigma-2 Receptor |
PROPRANOLOL |
Sigma2 |
72% |
3.467uM |
2.134uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
LOVASTATIN |
Calcium Channel Type L, Phenylalkylamine |
72% |
6.318uM |
6.142uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
LOVASTATIN |
Calcium Channel Type L, Phenylalkylamine |
72% |
6.318uM |
6.142uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
LOVASTATIN |
Calcium Channel Type L, Phenylalkylamine |
72% |
6.318uM |
6.142uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
LOVASTATIN |
Calcium Channel Type L, Phenylalkylamine |
72% |
6.318uM |
6.142uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
LOVASTATIN |
Calcium Channel Type L, Phenylalkylamine |
72% |
6.318uM |
6.142uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
LOVASTATIN |
Calcium Channel Type L, Phenylalkylamine |
72% |
6.318uM |
6.142uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
LOVASTATIN |
Calcium Channel Type L, Phenylalkylamine |
72% |
6.318uM |
6.142uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
LOVASTATIN |
Calcium Channel Type L, Phenylalkylamine |
72% |
6.318uM |
6.142uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
LOVASTATIN |
Calcium Channel Type L, Phenylalkylamine |
72% |
6.318uM |
6.142uM |
View
|
| sodium channel, voltage-gated, type VII, alpha |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
LOVASTATIN |
Calcium Channel Type L, Phenylalkylamine |
72% |
6.318uM |
6.142uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
LOVASTATIN |
Calcium Channel Type L, Phenylalkylamine |
72% |
6.318uM |
6.142uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
LOVASTATIN |
Calcium Channel Type L, Phenylalkylamine |
72% |
6.318uM |
6.142uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
LOVASTATIN |
Calcium Channel Type L, Phenylalkylamine |
72% |
6.318uM |
6.142uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
LOVASTATIN |
Calcium Channel Type L, Phenylalkylamine |
72% |
6.318uM |
6.142uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
LOVASTATIN |
Calcium Channel Type L, Phenylalkylamine |
72% |
6.318uM |
6.142uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
LOVASTATIN |
Calcium Channel Type L, Phenylalkylamine |
72% |
6.318uM |
6.142uM |
View
|
| mu-opioid receptor MOR |
CHLORPROMAZINE |
Opiate mu |
72% |
14.397uM |
5.844uM |
View
|
| cholinergic receptor, muscarinic 4 |
AMIODARONE |
Muscarinic M4 |
72% |
3.63uM |
.506uM |
View
|
| matrix metallopeptidase 9 |
CATECHOL |
Protease, Matrix Metalloprotease-9 (MMP-9) |
72% |
23.367uM |
NoneNone |
View
|
| matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) |
CATECHOL |
Protease, Matrix Metalloprotease-9 (MMP-9) |
72% |
23.367uM |
NoneNone |
View
|
| sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type IV, beta |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type IV, alpha |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type III, alpha |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type II, beta |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type II, alpha 2 |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type I, beta |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type I, alpha |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type IV, beta |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel associated protein 1 |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel associated protein 2 |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type III, beta |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type I, alpha |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type IX, alpha |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| cholinergic receptor, muscarinic 1 |
TACRINE |
Muscarinic M1 |
69% |
NoneNone |
NoneNone |
View
|
| amiloride-sensitive cation channel 5, intestinal |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type III, beta |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type VIII, alpha polypeptide |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
DIHYDROERGOTAMINE |
Sodium Channel, Site 2 |
72% |
5.058uM |
4.614uM |
View
|
| potassium voltage-gated channel, subfamily H, member 8 |
CHLORPROMAZINE |
Potassium Channel HERG |
72% |
5.8275uM |
4.7743uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 6 |
CHLORPROMAZINE |
Potassium Channel HERG |
72% |
5.8275uM |
4.7743uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 7 |
CHLORPROMAZINE |
Potassium Channel HERG |
72% |
5.8275uM |
4.7743uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 2 |
CHLORPROMAZINE |
Potassium Channel HERG |
72% |
5.8275uM |
4.7743uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 5 |
CHLORPROMAZINE |
Potassium Channel HERG |
72% |
5.8275uM |
4.7743uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 3 |
CHLORPROMAZINE |
Potassium Channel HERG |
72% |
5.8275uM |
4.7743uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 4 |
CHLORPROMAZINE |
Potassium Channel HERG |
72% |
5.8275uM |
4.7743uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 1 |
CHLORPROMAZINE |
Potassium Channel HERG |
72% |
5.8275uM |
4.7743uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
BW-723C86 |
Calcium Channel Type L, Benzothiazepine |
73% |
3.4696uM |
3.0841uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
BW-723C86 |
Calcium Channel Type L, Benzothiazepine |
73% |
3.4696uM |
3.0841uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
BW-723C86 |
Calcium Channel Type L, Benzothiazepine |
73% |
3.4696uM |
3.0841uM |
View
|
| cholinergic receptor, muscarinic 5 |
SULOCTIDIL |
Muscarinic M5 |
73% |
4.4868uM |
3.2235uM |
View
|
| solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
DOMPERIDONE |
Serotonin Transporter |
73% |
3.055uM |
1.623uM |
View
|
| mitogen activated protein kinase 3 |
ZAFIRLUKAST |
Protein Serine/Threonine Kinase, ERK1 |
73% |
4.376uM |
NoneNone |
View
|
| mitogen-activated protein kinase 3 |
ZAFIRLUKAST |
Protein Serine/Threonine Kinase, ERK1 |
73% |
4.376uM |
NoneNone |
View
|
| cholinergic receptor, muscarinic 1 |
MONTELUKAST |
Muscarinic M1 |
73% |
8.045uM |
1.938uM |
View
|
| cholinergic receptor, muscarinic 1 |
METHAPYRILENE |
Muscarinic M1 |
73% |
4.773uM |
1.15uM |
View
|
| dopamine receptor D3 |
MONTELUKAST |
Dopamine D3 |
73% |
7.747uM |
2.631uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
DESLORATADINE |
Calcium Channel Type L, Benzothiazepine |
73% |
5.791uM |
5.148uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
DESLORATADINE |
Calcium Channel Type L, Benzothiazepine |
73% |
5.791uM |
5.148uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
DESLORATADINE |
Calcium Channel Type L, Benzothiazepine |
73% |
5.791uM |
5.148uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1A |
PHENELZINE |
Serotonin 5-HT1A |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
DESLORATADINE |
Calcium Channel Type L, Benzothiazepine |
73% |
5.791uM |
5.148uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
DESLORATADINE |
Calcium Channel Type L, Benzothiazepine |
73% |
5.791uM |
5.148uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
DESLORATADINE |
Calcium Channel Type L, Benzothiazepine |
73% |
5.791uM |
5.148uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
DESLORATADINE |
Calcium Channel Type L, Benzothiazepine |
73% |
5.791uM |
5.148uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
DESLORATADINE |
Calcium Channel Type L, Benzothiazepine |
73% |
5.791uM |
5.148uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
DESLORATADINE |
Calcium Channel Type L, Benzothiazepine |
73% |
5.791uM |
5.148uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
DESLORATADINE |
Calcium Channel Type L, Benzothiazepine |
73% |
5.791uM |
5.148uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
DESLORATADINE |
Calcium Channel Type L, Benzothiazepine |
73% |
5.791uM |
5.148uM |
View
|